Toho HD's Poison Pill Passed at 54.70% — the Tightest Vote of the 2026 AGM Season
Toho HD's poison pill against 3D Investment Partners passed with 54.70% of the vote at the June 26, 2026 AGM — the tightest margin of any resolution logged this AGM season, activist-led or not. Glass Lewis had recommended against it; 3D ran a five-year campaign that included a white paper, a 17-point FAQ rebuttal, and a manga comic. The pill passed regardless, but by less than any other vote in Quorum's 2026 dataset.
| Target | Toho Holdings Co., Ltd., ticker 8129 (pharmaceutical wholesaler) |
|---|---|
| Activist | 3D Investment Partners — holding since July 2020, ~24% of voting rights by May 2026 |
| Proposal | Proposal 4: gratis allotment of stock acquisition rights (poison pill trigger authorization) |
| Vote result | 54.70% in favor — passed (simple majority required) |
| Same-day director votes | 60.78%–66.56%; CEO Hiromi Edahiro's own reappointment at 60.78%, six points below every other director |
| Proxy adviser | Glass Lewis recommended against the poison pill (2026-06-07) |
| AGM date | 2026-06-26 |
| Board defense policy adopted | 2025-10-31, after 3D's stake grew |
| Effect of passage | Not self-executing — board may trigger only if 3D doesn't cease/withdraw the classified large-scale purchase; authority expires at the board meeting following the 2027 AGM |
| Primary source | 臨時報告書 S100YMUC (filed 2026-06-29) |
Five years, one rising stake
3D Investment Partners has held a position in Toho HD since July 2020. By late 2025 the fund's stake had grown enough that Toho's board adopted a formal takeover-defense response policy on 2025-10-31 — the framework Japanese companies use to justify a poison pill. In January 2026, 3D disclosed it might raise its stake to as much as 27%. By June, 3D held approximately 24% of voting rights.
3D did not go quietly: the fund published a full white paper, a 17-point FAQ rebuttal, a dedicated campaign website, and a manga comic laying out its case to shareholders. Glass Lewis recommended shareholders vote against the poison pill.
The vote, against the rest of the season
Proposal 4 passed at 54.70% — not a defeat for the company, but far tighter than the rest of this AGM season produced for management's side. Toho's own director reappointments passed the same day at 60.78% to 66.56%. Even KADOKAWA's CEO, down 30 points from the prior year and facing a dismissal proposal from a 15%-plus activist stake, still cleared 59.68%. Toho's poison pill, at 54.70%, is the tightest margin logged this season on either side of the ledger.
CEO Hiromi Edahiro's own reappointment passed at 60.78% — six points below every other director on the slate, who each cleared 66% or higher. The filing doesn't explain the gap; a shareholder base that reappoints five directors comfortably and the CEO six points less comfortably is telling you something about where the discomfort concentrated.
What the vote actually authorizes
The poison pill's passage is not self-executing. Under its terms, the board can only trigger the gratis allotment if 3D does not cease or withdraw what Toho classifies as a large-scale purchase — and the authority to do so expires at the board meeting following the 2027 AGM. The vote grants standing permission, not an immediate dilution.
Part of the same dataset
Toho HD extends the Japan AGM season 2026 vote results Quorum has tracked at KADOKAWA, Kyocera, HORIBA, and Iyogin Holdings. Those four showed a structural floor — domestic anchor shareholders voting with management — holding at 59.68% to 99% for routine business. Toho is the season's first test of that floor against a company's own extraordinary ask, and it bent further here than anywhere else logged so far.
FAQ
- What percentage did Toho HD's poison pill receive?
- 54.70% in favor — passed, the tightest margin of the 2026 AGM season in Quorum's dataset.
- Who was it aimed at?
- 3D Investment Partners, holding ~24% of voting rights after a campaign dating to July 2020.
- Did Glass Lewis support it?
- No — Glass Lewis recommended voting against the poison pill (2026-06-07). It passed anyway, narrowly.
- Where can I verify this?
- Primary EDINET filing S100YMUC.